Post-earnings recap
Reported
Thu, Aug 2, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin Pharmaceuticals reported a loss per share that was significantly worse than expected, yet the stock rose by 1.07%. This increase may reflect investor confidence in the company's long-term strategies despite the EPS miss. The lack of revenue guidance suggests uncertainty about future performance, but management's focus on long-term goals may have reassured some investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | -156.53% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing projects and long-term growth.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its long-term strategies despite the current EPS shortfall.